Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Karen J. Wilson sold 3,760 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $165.00, for a total value of $620,400.00. Following the transaction, the senior vice president now owns 15,811 shares in the company, valued at approximately $2,608,815. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ:JAZZ opened at $165.01 on Friday. Jazz Pharmaceuticals has a 52 week low of $160.05 and a 52 week high of $163.09. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $9.67 billion, a price-to-earnings ratio of 16.35, a price-to-earnings-growth ratio of 0.83 and a beta of 0.97.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The business had revenue of $436.40 million during the quarter, compared to analysts’ expectations of $440.91 million. research analysts predict that Jazz Pharmaceuticals will post 11.65 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. US Bancorp DE raised its holdings in shares of Jazz Pharmaceuticals by 49.5% in the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after buying an additional 360 shares during the period. We Are One Seven LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $157,000. Financial Gravity Companies Inc. raised its holdings in shares of Jazz Pharmaceuticals by 124.6% in the 1st quarter. Financial Gravity Companies Inc. now owns 1,271 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 705 shares during the period. Brighton Jones LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at $205,000. Finally, Invictus RG purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at $206,000. Hedge funds and other institutional investors own 90.62% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.